Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technology

"If large multinational pharmaceutical companies are allowed to illegally exploit the research and innovation of companies like Factor, it will have a chilling effect on future innovations and ultimately delay the development of new therapies," Factor CEO Matt Angel said in a statement.

As per reuters, the lawsuit said that Cambridge, Massachusetts-based Factor developed novel techniques for using messenger RNA and proteins, called TALENs, to produce cells to fight cancers like leukemia and lymphoma. Factor alleged that France-based Cellectis copied its mRNA TALEN technology to develop its own leukemia and lymphoma treatments.

United Kingdom-based AstraZeneca agreed in 2023 to license Cellectis' gene-editing technology to help develop therapeutics in fields including oncology, immunology and rare diseases. Factor's lawsuit accused AstraZeneca of violating its patent rights by using Cellectis' technology.

Factor requested an unspecified amount of monetary damages for the alleged infringement.

"Since the discovery of the structure of DNA, there has been interest in developing methods to reprogram cells by editing their genetic code to treat disease and improve health," Factor said in the lawsuit. "There are billions of dollars at stake in being the first company to develop such breakthrough treatments."

The case is Factor Bioscience Inc v. Cellectis Inc, U.S. District Court for the District of Delaware, No. 1:25-cv-01197

For Factor: Robert Cerwinski, Michael Johnson and Lora Green of Gemini Law; Huiya Wu and Linnea Cipriano of Goodwin Procter

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technology

Similar News

Himachal Drug Makers Unfazed by US 100% Tariff on Branded Drugs

India's generic drugs safe as Trump targets branded pharma imports: Experts

CDSCO Panel Approves Novo Medi Sciences' Phase III Booster Study of PCV13 Pneumococcal Vaccine in Infants

Aurobindo Pharma arm CuraTeQ Biologics incorporates new wholly owned subsidiary in Malta

Alkem Labs transfers trade generics business to Alkem Wellness

Telangana: Congress MLA warns to burn pharma unit over alleged pollution

No Tariff for Pharma Firms with US Facilities, Says Trump as 100% Duty on Branded Drug Imports Kicks In